GET DAILY SIGNALSDentsply Sirona (XRAY) +23% in 30 Days: Drivers Behind the Recent Rebound
Key Takeaways
- Dentsply Sirona (XRAY) shares climbed roughly 23% over the past 30 days, rebounding from about $8.56 in early October to near $10.54.
- The recovery followed a series of commercial, reimbursement, and balance-sheet developments, including expanded North American distribution partnerships and debt covenant relief.
- The rally came after a steep multi-month decline; over the last quarter the stock is still down around 26% from its early-August levels.
- Demand softness in dental implants, orthodontics, and equipment, along with cautious guidance and tariff pressures, has weighed on the broader turnaround narrative.
- The company maintained its full-year 2026 outlook of $3.5 billion to $3.6 billion in net sales and adjusted EPS of $1.40 to $1.50.
Company Overview and Market Position
Dentsply Sirona (XRAY) is the world's largest diversified manufacturer of professional dental products and technologies. Headquartered in Charlotte, North Carolina, the company was formed through the 2016 combination of Dentsply International and Sirona Dental Systems. Its portfolio spans dental consumables, laboratory products, implants, connected equipment, and digital dentistry solutions such as CAD/CAM systems and the SureSmile clear-aligner platform. Through its Wellspect HealthCare subsidiary, the company also supplies urology and continence-care medical devices.
The company sells into dental practices, laboratories, and institutions globally, and it has been expanding its North American dealer network to broaden access to its connected technology ecosystem. Investors follow XRAY as a bellwether for elective dental procedure demand and as a turnaround story centered on cost discipline, commercial execution, and digital dentistry adoption. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, XRAY has gained approximately 23%, rising from a closing level near $8.56 in early October to roughly $10.54. The move marked a sharp reversal after the stock bottomed in the low-$8 range in mid-to-late October.
The longer-term picture remains more challenging. Measured over the last quarter, the stock is still down roughly 26% from its early-August level near $14.27. That decline reflects a pullback that began in the summer, when second-quarter results renewed concerns about dental demand, and continued into October before the recent rebound took hold. From what I see, the price action aligns with broader sector trends during this period.
Key Drivers of the 30-Day Recovery
Several verified developments coincided with the stock's recovery. In early October, Dentsply Sirona announced an expanded distribution agreement with Midwest Dental Equipment & Supply, extending the relationship beyond consumables to include the company's technology portfolio effective November 1, 2026. The move marked the company's seventh North American dealer partnership enhancement of the year, broadening access to its digital dentistry ecosystem.
Around the same time, the company's Wellspect HealthCare subsidiary announced that its Surity urinary-management portfolio could qualify for traditional U.S. Medicare reimbursement for eligible patients. Dentsply Sirona also disclosed that lenders had consented to amendments to its revolving credit facility and related note agreements, providing covenant relief and reducing near-term balance-sheet pressure. The subsequent confirmation of a third-quarter earnings call scheduled for November 5, 2026 helped sustain the momentum into early November. I reviewed the latest signals on this using Tickeron’s AI Daily Buy/Sell Signals to cross-check timing.
Factors Behind the Quarterly Decline
The quarterly decline was driven primarily by fundamental concerns rather than a single event. Second-quarter results, reported in early August, beat earnings and revenue estimates but showed net sales down about 4% as weaker demand for implants, orthodontics, and dental equipment offset growth at Wellspect. Management maintained its full-year guidance, but cautious commentary and continued margin pressure weighed on sentiment.
Broader factors also played a role, including tariff-related cost exposure, softness in elective dental procedures, and investor caution around the pace of the company's turnaround and restructuring efforts. The recent distribution expansion and covenant relief have begun to reframe that narrative, though the stock remains well below its 52-week high.
What to Watch Next for XRAY
The most immediate catalyst is the company's third-quarter earnings report and conference call scheduled for November 5, 2026. Investors will be watching revenue trends across dental consumables, implants, and digital dentistry, as well as any updates to the 2026 outlook of $3.5 billion to $3.6 billion in net sales and adjusted EPS of $1.40 to $1.50.
Beyond earnings, key factors include the pace of the North American distribution reset, demand recovery in elective and preventive dental procedures, tariff and trade-policy developments, and continued progress on cost and restructuring initiatives. Analyst expectations and any revisions to price targets will also influence sentiment, as will the company's ability to sustain the recent balance-sheet and commercial momentum. I’m watching this closely as the earnings date approaches.
Using AI Tools for Market Context
In my view, automated strategies can offer useful perspective on how similar names are behaving in the current environment. Tickeron’s Trending AI Robots section highlights top-performing bots across various tickers and timeframes, allowing investors to observe data-driven positioning without needing to build models from scratch. This resource has helped me quickly scan for relevant patterns in sectors like healthcare equipment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XRAY's RSI Indicator climbs out of oversold territory
The RSI Indicator for XRAY moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 30 of the 42 cases the stock moved higher. This puts the odds of a move higher at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XRAY as a result. In 59 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for XRAY just turned positive on October 09, 2026. Looking at past instances where XRAY's MACD turned positive, the stock continued to rise in 27 of 53 cases over the following month. The odds of a continued upward trend are 51%.
XRAY moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in 172 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
XRAY broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XRAY entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.436) is normal, around the industry mean (4.946). P/E Ratio (-3.564) is within average values for comparable stocks, (38.797). Projected Growth (PEG Ratio) (0.601) is also within normal values, averaging (4.143). XRAY's Dividend Yield (0.066) is considerably higher than the industry average of (0.005). P/S Ratio (0.557) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. XRAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Bitcoin’s Source Code, Pt 1: What Does Open-Source Mean?
What is the definition of consolidation?
What Is Stagflation, and How Does It Impact Economies?
AI Trading Bots: Top 10 Day Traders, Signals Only, on October 20, 2024
TCOM, LU, ZIM, HD, PANW, BILI, PONY, TJX, LOW, SNOW, TGT, BIDU, ZM, BBY, GES | Q1 2025 Earnings Preview: May 19-21, 2025
General Information
a global denal eqipment company
Industry PharmaceuticalsOther
Advertisement